Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setipiprant in Seasonal Allergic Rhinitis
NCT01241214Phase 2Completed
- Sponsor
- Idorsia
- Start
- Nov 2010
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of setipiprant in seasonal allergic rhinitis (SAR) (6 arms), sponsored by Idorsia. Primary endpoint: Daytime Nasal Symptom Score. Started Nov 2010; status: completed.
02
Drugs
setipiprant
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT01241214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01241214.